Liang Gu, Guangjuan Ke, Yizhi Ge, Wenxuan Huang, Yi Peng, Junling Zhang, Xia He
{"title":"A study on the correlation between SIRT6 gene polymorphisms and glioma risk in Chinese Han population.","authors":"Liang Gu, Guangjuan Ke, Yizhi Ge, Wenxuan Huang, Yi Peng, Junling Zhang, Xia He","doi":"10.1080/00207454.2025.2584082","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioma is a common type of cancer of the central nervous system. Sirtuin 6 (SIRT6) has been reported to be a tumor suppressor in gliomas. The relationship between SIRT6 and glioma susceptibility is unknown. We aimed to investigate the association between single nucleotide polymorphisms (SNPs) of SIRT6 and the risk of glioma.</p><p><strong>Methods: </strong>205 glioma patients and 225 healthy controls were included in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the transcription level of SIRT6 in the plasma of patients and healthy individuals.</p><p><strong>Results: </strong>The distribution of the A allele of rs350843 and the C allele of rs352493 in SIRT6 was significantly lower in glioma patients (All <i>p</i> < 0.001). The distribution of the T allele of rs11878868 was significantly higher in glioma patients (<i>p</i> < 0.001). The distribution of the genotypes of the rs352493 and rs11878868 polymorphisms were independent risk predictor factors (All <i>p</i> < 0.01). Furthermore, we found that the expression of SIRT6 in glioma patients was lower compared with control group (<i>p</i> < 0.001). The expression level of SIRT6 was lower in glioma patients with the TT genotype at rs11878868 (All <i>p</i> < 0.01). There was no significant difference in the rs352493 and rs11878868 genotypes among the different subtypes (All <i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>These results indicate that SIRT6 polymorphism is associated with the risk of glioma and has the potential to be used as a marker for predicting glioma.</p>","PeriodicalId":14161,"journal":{"name":"International Journal of Neuroscience","volume":" ","pages":"508-516"},"PeriodicalIF":1.7000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00207454.2025.2584082","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Glioma is a common type of cancer of the central nervous system. Sirtuin 6 (SIRT6) has been reported to be a tumor suppressor in gliomas. The relationship between SIRT6 and glioma susceptibility is unknown. We aimed to investigate the association between single nucleotide polymorphisms (SNPs) of SIRT6 and the risk of glioma.
Methods: 205 glioma patients and 225 healthy controls were included in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the transcription level of SIRT6 in the plasma of patients and healthy individuals.
Results: The distribution of the A allele of rs350843 and the C allele of rs352493 in SIRT6 was significantly lower in glioma patients (All p < 0.001). The distribution of the T allele of rs11878868 was significantly higher in glioma patients (p < 0.001). The distribution of the genotypes of the rs352493 and rs11878868 polymorphisms were independent risk predictor factors (All p < 0.01). Furthermore, we found that the expression of SIRT6 in glioma patients was lower compared with control group (p < 0.001). The expression level of SIRT6 was lower in glioma patients with the TT genotype at rs11878868 (All p < 0.01). There was no significant difference in the rs352493 and rs11878868 genotypes among the different subtypes (All p > 0.05).
Conclusions: These results indicate that SIRT6 polymorphism is associated with the risk of glioma and has the potential to be used as a marker for predicting glioma.
背景:神经胶质瘤是一种常见的中枢神经系统肿瘤。Sirtuin 6 (SIRT6)已被报道为神经胶质瘤中的肿瘤抑制因子。SIRT6与胶质瘤易感性之间的关系尚不清楚。我们的目的是研究SIRT6的单核苷酸多态性(snp)与胶质瘤风险之间的关系。方法:选取205例胶质瘤患者和225例正常人作为研究对象。聚合酶链反应-限制性片段长度多态性(PCR-RFLP)。采用逆转录-定量聚合酶链反应(RT-qPCR)检测患者和健康人血浆中SIRT6的转录水平。结果:胶质瘤患者SIRT6中rs350843的A等位基因和rs352493的C等位基因的分布显著降低(P P P P P P >.05)。结论:这些结果表明SIRT6多态性与胶质瘤的风险相关,并有可能作为预测胶质瘤的标志物。
期刊介绍:
The International Journal of Neuroscience publishes original research articles, reviews, brief scientific reports, case studies, letters to the editor and book reviews concerned with problems of the nervous system and related clinical studies, epidemiology, neuropathology, medical and surgical treatment options and outcomes, neuropsychology and other topics related to the research and care of persons with neurologic disorders. The focus of the journal is clinical and transitional research. Topics covered include but are not limited to: ALS, ataxia, autism, brain tumors, child neurology, demyelinating diseases, epilepsy, genetics, headache, lysosomal storage disease, mitochondrial dysfunction, movement disorders, multiple sclerosis, myopathy, neurodegenerative diseases, neuromuscular disorders, neuropharmacology, neuropsychiatry, neuropsychology, pain, sleep disorders, stroke, and other areas related to the neurosciences.